Fecal Microbiota-based Therapies for Select Gastrointestinal Disease
Key Points
Key Points
- Fecal microbiota-based therapies include conventional fecal microbiota transplant (FMT) and US Food and Drug Administration (FDA)-approved therapies, fecal microbiota live-jslm and fecal microbiota spores live-brpk.
- This guideline provides recommendations on the use of fecal microbiota-based therapies in adults with recurrent Clostridioides difficile infection (CDI), severe to fulminant C. difficile infection and inflammatory bowel diseases (IBDs) including pouchitis, ulcerative colitis (UC) and irritable bowel syndrome (IBS).
Treatment
...eatmen...
...tion 1In immunocompetent adults with recurrent...
...owing considerations are specific to...
...(part 1)In mildly or moderately immunocompromis...
...moderately immunocompromised adults are...
...tion 2 (part 2)In severely immunocompromised...
...everely immunocompromised includes patients...
Recommendation 3In adults hospitalized with severe...
...owing considerations are specific to...
...4In adults with ulcerative colitis, the AG...
...Conventional FMT can reasonably be used in...
...dation 5In adults with Crohn’s disease...
...mmendation is specific to the use of conven...
...commendation 6In adults with pouchitis...
The recommendation is specific to the use of c...
...tion 7In adults with irritable bowel syndrome, th...
...endation is specific to the use of conventional F...
.... Use of Fecal Microbiota-Based Therapies in...